查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1319063

腫瘤生物相似藥市場：用途（癌症藥物、支持性護理藥物）、最終用戶（醫院、零售藥房）分類 - 2023-2030 年全球預測

Oncology Biosimilars Market by Application (Cancer Treatment Drugs, Supportive Care Drugs), End-User (Hospitals, Retail Pharmacies) - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年全球腫瘤生物相似藥市場將達到46.5176億美元，複合年成長率為18.09%，大幅成長，2030年將達到149.1629億美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球腫瘤生物相似藥市場至關重要。透過檢驗業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使用戶能夠根據自己的具體需求做出資訊的決策。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發領域、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.腫瘤生物相似藥的全球市場規模與預測為何？

2.在預測期內，COVID-19對全球腫瘤生物相似藥市場的阻礙因素和影響為何？

3.全球腫瘤生物相似藥市場在預測期內應投資哪些產品/細分市場/應用/領域？

4.你們在全球腫瘤生物相似藥市場的競爭策略是什麼？

5.全球腫瘤生物相似藥市場的技術趨勢和法律規範是什麼？

6.全球腫瘤生物相似藥市場主要廠商的市佔率為何？

7. 您認為腫瘤生物相似藥進入全球市場的合適型態和策略性舉措是什麼？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 促進因素
      • 產品商業化的快速法規核准
      • 各種癌症和白血病的發生率增加
      • 臨床藥物開發的最新創新
    • 抑制因素
      • 調查費用昂貴
    • 機會
      • 介紹新的和創新的治療方案
      • 策略聯盟投資與產能擴張
    • 任務
      • 有限的臨床安全性和有效性資料
  • 市場趨勢
  • COVID-19 的累積影響
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範
  • 客戶客製化

第6章 腫瘤生物相似藥市場：依用途

  • 癌症治療藥物
  • 支持治療藥物

第7章 腫瘤生物相似藥市場：依最終用戶分類

  • 醫院
  • 零售藥房

第8章 美洲腫瘤生物相似藥市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章 亞太腫瘤生物相似藥市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲的腫瘤生物相似藥市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭形勢

  • FPNV定位矩陣
  • 市佔率分析：主要企業
  • 競爭情境分析：主要企業

第12章上市公司名單

第13章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-036C5CF3A8CD

The Global Oncology Biosimilars Market is forecasted to grow significantly, with a projected USD 4,651.76 million in 2023 at a CAGR of 18.09% and expected to reach a staggering USD 14,916.29 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Oncology Biosimilars Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Oncology Biosimilars Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Application, market is studied across Cancer Treatment Drugs and Supportive Care Drugs. The Cancer Treatment Drugs is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Hospitals and Retail Pharmacies. The Hospitals is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Oncology Biosimilars Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Oncology Biosimilars Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Oncology Biosimilars Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Oncology Biosimilars Market?

4. What is the competitive strategic window for opportunities in the Global Oncology Biosimilars Market?

5. What are the technology trends and regulatory frameworks in the Global Oncology Biosimilars Market?

6. What is the market share of the leading vendors in the Global Oncology Biosimilars Market?

7. What modes and strategic moves are considered suitable for entering the Global Oncology Biosimilars Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Oncology Biosimilars Market, by Application, 2022 vs 2030
  • 4.3. Oncology Biosimilars Market, by End-User, 2022 vs 2030
  • 4.4. Oncology Biosimilars Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rapid approval by regulatory authorities for commercialization of products
      • 5.1.1.2. Rising incidence of various types of cancers and leukemia
      • 5.1.1.3. Recent innovation in clinical drug development
    • 5.1.2. Restraints
      • 5.1.2.1. High costs involved in the research
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of new and innovative treatment options
      • 5.1.3.2. Strategic alliances and investment for capacity expansion
    • 5.1.4. Challenges
      • 5.1.4.1. Limited clinical safety and efficacy data
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Oncology Biosimilars Market, by Application

  • 6.1. Introduction
  • 6.2. Cancer Treatment Drugs
  • 6.3. Supportive Care Drugs

7. Oncology Biosimilars Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Retail Pharmacies

8. Americas Oncology Biosimilars Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Oncology Biosimilars Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Oncology Biosimilars Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ONCOLOGY BIOSIMILARS MARKET RESEARCH PROCESS
  • FIGURE 2. ONCOLOGY BIOSIMILARS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
  • FIGURE 5. ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
  • FIGURE 6. ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 7. ONCOLOGY BIOSIMILARS MARKET DYNAMICS
  • FIGURE 8. ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ONCOLOGY BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 15. ONCOLOGY BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. ONCOLOGY BIOSIMILARS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 5. ONCOLOGY BIOSIMILARS MARKET SIZE, BY CANCER TREATMENT DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. ONCOLOGY BIOSIMILARS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 8. ONCOLOGY BIOSIMILARS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ONCOLOGY BIOSIMILARS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 11. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 13. ARGENTINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. ARGENTINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 16. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 22. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. INDONESIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. INDONESIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. MALAYSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. MALAYSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. PHILIPPINES ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. PHILIPPINES ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. SINGAPORE ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. SINGAPORE ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. TAIWAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. TAIWAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. THAILAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. THAILAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. VIETNAM ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. VIETNAM ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. DENMARK ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. DENMARK ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. EGYPT ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. EGYPT ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. FINLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. FINLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. ISRAEL ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. ISRAEL ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. NETHERLANDS ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. NETHERLANDS ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. NIGERIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. NIGERIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. NORWAY ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. NORWAY ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. POLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. POLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. QATAR ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. QATAR ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. SAUDI ARABIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. SAUDI ARABIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. SOUTH AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. SWEDEN ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SWEDEN ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. SWITZERLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SWITZERLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. TURKEY ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TURKEY ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED ARAB EMIRATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED ARAB EMIRATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. ONCOLOGY BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 97. ONCOLOGY BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 98. ONCOLOGY BIOSIMILARS MARKET LICENSE & PRICING